|
US9829494B2
(en)
|
2005-12-01 |
2017-11-28 |
Adrenomed Ag |
Methods of treatment using ADM antibodies
|
|
EP2371865B1
(en)
|
2006-04-07 |
2017-07-12 |
Aerpio Therapeutics, Inc. |
Antibodies that bind human protein tyrosine phosphatase beta (HPTP-ß) and uses thereof
|
|
TWI510246B
(zh)
|
2010-04-30 |
2015-12-01 |
Molecular Partners Ag |
抑制vegf-a受體交互作用的經修飾結合性蛋白質
|
|
AU2014243418B2
(en)
*
|
2010-04-30 |
2016-09-22 |
Molecular Partners Ag |
Modified binding proteins inhibiting the VEGF-A receptor interaction
|
|
AU2011333666B2
(en)
*
|
2010-11-26 |
2017-02-02 |
Molecular Partners Ag |
Improved capping modules for designed ankyrin repeat proteins
|
|
CA2834624A1
(en)
|
2011-04-29 |
2012-11-01 |
Janssen Biotech, Inc. |
Il4/il13 binding repeat proteins and uses
|
|
WO2012172054A1
(en)
|
2011-06-16 |
2012-12-20 |
Scil Proteins Gmbh |
Modified multimeric ubiquitin proteins binding vegf-a
|
|
CA2850830A1
(en)
|
2011-10-13 |
2013-04-18 |
Aerpio Therapeutics, Inc. |
Methods for treating vascular leak syndrome and cancer
|
|
PT2780370T
(pt)
|
2011-11-16 |
2019-10-30 |
Adrenomed Ag |
Anticorpo anti-adrenomedulina (adm) ou fragmento anticorpo anti-adm ou estrutura de anticorpo anti-adm não ig para utilização na terapia de uma doença aguda ou condição aguda de um paciente para estabilizar a circulação
|
|
EP2594588B1
(en)
|
2011-11-16 |
2014-05-21 |
AdrenoMed AG |
Anti-Adrenomedullin (ADM) antibody or anti-ADM antibody fragment or an anti-ADM non-Ig protein scaffold for use in therapy
|
|
ES2494190T3
(es)
|
2011-11-16 |
2014-09-15 |
Adrenomed Ag |
Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje proteico sin Ig anti-ADM para reducir el riesgo de mortalidad en un paciente que padece una enfermedad crónica o aguda o un estado agudo
|
|
CN104067130B
(zh)
|
2011-11-16 |
2017-02-22 |
斯弗因高泰克有限公司 |
肾上腺髓质素测定与用于确定成熟肾上腺髓质素的方法
|
|
SG10202006318TA
(en)
|
2011-11-16 |
2020-08-28 |
Adrenomed Ag |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
|
|
PT2780371T
(pt)
|
2011-11-16 |
2019-01-30 |
Adrenomed Ag |
Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou uma estrutura não ig anti-adm para a regulação do equilíbrio de fluidos num doente com uma doença aguda ou crónica
|
|
CN103308689B
(zh)
|
2012-03-08 |
2017-04-12 |
思芬构技术有限公司 |
用于预测雌性对象中患上癌症的风险或诊断癌症的方法
|
|
CN103308673B
(zh)
|
2012-03-08 |
2017-05-31 |
思芬构技术有限公司 |
用于预测雌性对象中发生心血管事件的风险的方法
|
|
CN103308670B
(zh)
|
2012-03-08 |
2017-06-09 |
思芬构技术有限公司 |
用于预测对象患糖尿病和/或代谢综合征的风险的方法
|
|
DK2846836T3
(da)
*
|
2012-05-07 |
2019-11-11 |
Allergan Inc |
Fremgangsmåde til behandling af amd hos patienter, der er refraktære overfor anti-vegf-terapi
|
|
LT3536310T
(lt)
|
2012-06-01 |
2021-07-26 |
Novartis Ag |
Švirkštas
|
|
AU2013283296A1
(en)
|
2012-06-28 |
2015-02-05 |
Molecular Partners Ag |
Designed ankyrin repeat proteins binding to platelet-derived growth factor
|
|
JOP20200175A1
(ar)
|
2012-07-03 |
2017-06-16 |
Novartis Ag |
حقنة
|
|
AU2012101678B4
(en)
*
|
2012-07-03 |
2013-01-24 |
Novartis Ag |
Use of device
|
|
AU2013100071C4
(en)
*
|
2012-07-03 |
2013-05-02 |
Novartis Ag |
Device
|
|
JP2015528454A
(ja)
*
|
2012-08-28 |
2015-09-28 |
ノバルティス アーゲー |
眼血管増殖性疾患の処置におけるvegfアンタゴニストの使用
|
|
EP3361260B1
(en)
|
2012-10-02 |
2020-06-10 |
sphingotec GmbH |
A method for diagnosing or monitoring kidney function
|
|
EP2738180A1
(en)
|
2012-11-30 |
2014-06-04 |
Molecular Partners AG |
Binding proteins comprising at least two binding domains against HER2.
|
|
CN107991501A
(zh)
|
2013-01-08 |
2018-05-04 |
斯弗因高泰克有限公司 |
生长激素的禁食水平作为心血管风险的预测标志物
|
|
CA2896370A1
(en)
*
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
KR20150128857A
(ko)
*
|
2013-03-14 |
2015-11-18 |
알러간, 인코포레이티드 |
지속된-방출 전달의 조성물 및 제조 공정 동안 단백질을 안정화시키는 방법
|
|
SG11201507774YA
(en)
|
2013-03-20 |
2015-10-29 |
Sphingotec Gmbh |
Adrenomedullin to guide therapy of blood pressure decline
|
|
FR3004650B1
(fr)
*
|
2013-04-22 |
2015-05-29 |
Affilogic |
Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation
|
|
JP6486908B2
(ja)
|
2013-05-31 |
2019-03-20 |
モレキュラー パートナーズ アクチェンゲゼルシャフト |
肝細胞増殖因子に結合する設計アンキリン反復タンパク質
|
|
EP3010525A1
(en)
|
2013-06-20 |
2016-04-27 |
Novartis AG |
Use of a vegf antagonist in treating choroidal neovascularisation
|
|
WO2014203183A1
(en)
|
2013-06-20 |
2014-12-24 |
Novartis Ag |
Use of a vegf antagonist in treating macular edema
|
|
JP2016522248A
(ja)
|
2013-06-20 |
2016-07-28 |
ノバルティス アーゲー |
ポリープ状脈絡膜血管症の治療
|
|
US20160159893A1
(en)
*
|
2013-07-11 |
2016-06-09 |
Gabriela Burian |
Use of a VEGF Antagonist in Treating Retinopathy of Prematurity
|
|
WO2015004616A1
(en)
*
|
2013-07-11 |
2015-01-15 |
Novartis Ag |
Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients
|
|
AU2014286996A1
(en)
|
2013-07-12 |
2016-01-07 |
Iveric Bio, Inc. |
Methods for treating or preventing ophthalmological conditions
|
|
HUE047910T2
(hu)
*
|
2013-11-05 |
2020-05-28 |
Allergan Inc |
Eljárás a szem állapotainak kezelésére anti-VEGF darpinnal
|
|
WO2015173260A1
(en)
|
2014-05-12 |
2015-11-19 |
Formycon Ag |
Pre-filled plastic syringe containing a vegf antagonist
|
|
US20160097781A1
(en)
|
2014-10-01 |
2016-04-07 |
Sphingotec Gmbh |
Method for stratifying a female subject for hormone replacement therapy
|
|
AU2016240220B2
(en)
*
|
2015-04-02 |
2019-11-21 |
Molecular Partners Ag |
Designed ankyrin repeat domains with binding specificity for serum albumin
|
|
CA2983542A1
(en)
|
2015-04-24 |
2016-10-27 |
Sphingotec Gmbh |
A method for predicting the risk of incidence of chronic kidney disease
|
|
TWI799366B
(zh)
|
2015-09-15 |
2023-04-21 |
美商建南德克公司 |
胱胺酸結骨架平臺
|
|
BR112018009953B1
(pt)
|
2015-11-18 |
2024-03-05 |
Formycon Ag |
Seringa farmacêutica pré-preenchida esterilizada, e, kit
|
|
BR112018010005A2
(pt)
|
2015-11-18 |
2018-11-21 |
Formycon Ag |
seringa pré-carregada, e, kit
|
|
US11654046B2
(en)
|
2015-11-18 |
2023-05-23 |
Sio2 Medical Products, Inc. |
Pharmaceutical package for ophthalmic formulations
|
|
JP6953433B2
(ja)
|
2016-01-26 |
2021-10-27 |
フォーマイコン アーゲーFormycon Ag |
Vegfアンタゴニストを含む液体医薬組成物および同医薬組成物を含有する充填済みシリンジ
|
|
CN109073660B
(zh)
|
2016-02-29 |
2022-10-28 |
麦恩泰科特有限公司 |
可用于治疗湿性年龄相关性黄斑变性的预测性标志物
|
|
SG11201809252YA
(en)
|
2016-04-21 |
2018-11-29 |
Sphingotec Therapeutics Gmbh |
Methods for determining dpp3 and therapeutic methods
|
|
MA45493A
(fr)
|
2016-06-27 |
2019-05-01 |
Aicuris Anti Infective Cures Gmbh |
Inhibiteurs d'entrée de hcmv.
|
|
SG11201900133WA
(en)
|
2016-07-08 |
2019-02-27 |
Sphingotec Gmbh |
Adrenomedullin for assessing congestion in a subject with acute heart failure
|
|
JP7107914B2
(ja)
|
2016-07-20 |
2022-07-27 |
アイポイント ファーマシューティカルズ, インコーポレイテッド |
VE-PTP(HPTP-β)を標的化するヒト化モノクローナル抗体
|
|
AR109680A1
(es)
|
2016-09-22 |
2019-01-09 |
Molecular Partners Ag |
Proteínas recombinantes y sus usos
|
|
EP3309550A1
(en)
|
2016-10-12 |
2018-04-18 |
sphingotec GmbH |
Method for the detection of apolipoprotein e4
|
|
EP3339324A1
(en)
|
2016-12-22 |
2018-06-27 |
sphingotec GmbH |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
|
|
MY208219A
(en)
|
2016-12-16 |
2025-04-24 |
Adrenomed Ag |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
|
|
WO2018215580A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Method for sterilizing prefilled plastic syringes containing a vegf antagonist
|
|
US20200171244A1
(en)
|
2017-05-24 |
2020-06-04 |
Sio2 Medical Products, Inc. |
Sterilizable pharmaceutical package for ophthalmic formulations
|
|
WO2018217995A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
|
|
JP7271442B2
(ja)
|
2017-05-30 |
2023-05-11 |
シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング |
腎機能を診断またはモニターする方法、または腎機能障害を診断することを補助する方法
|
|
TW201904610A
(zh)
|
2017-06-14 |
2019-02-01 |
德商拜耳製藥公司 |
用於治療新生血管型青光眼之非抗體vegf拮抗劑
|
|
WO2019020777A1
(en)
|
2017-07-26 |
2019-01-31 |
Formycon Ag |
LIQUID FORMULATION OF A VEGF ANTAGONIST
|
|
SG11202001420VA
(en)
*
|
2017-08-18 |
2020-03-30 |
Cambridge Entpr Ltd |
Modular binding proteins
|
|
MY204700A
(en)
|
2017-09-25 |
2024-09-10 |
Adrenomed Ag |
Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
|
|
SG11202002268XA
(en)
|
2017-10-18 |
2020-04-29 |
Adrenomed Ag |
Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder
|
|
SG11202002391PA
(en)
|
2017-10-24 |
2020-04-29 |
Sphingotec Gmbh |
Selenoprotein p for prediction of a first cardiovascular event
|
|
IL274009B2
(en)
|
2017-10-25 |
2025-01-01 |
4TEEN4 Pharmaceuticals GmbH |
DDP3-bound targeting and binding to specific epitopes of DDP3 and their use for the prevention or treatment of diseases/acute conditions associated with acidosis
|
|
MX421834B
(es)
|
2018-02-08 |
2025-03-14 |
Sphingotec Gmbh |
Adrenomedulina (adm) para el diagnostico y/o prediccion de demencia y un aglutinante de anti-adrenomedulina para usarse en la terapia o prevencion de demencia
|
|
EP3569614A1
(en)
|
2018-05-18 |
2019-11-20 |
Julius-Maximilians-Universität Würzburg |
Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
|
|
EP3586865A1
(en)
|
2018-06-21 |
2020-01-01 |
Charité - Universitätsmedizin Berlin |
Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
|
|
CN113164597B
(zh)
|
2018-09-24 |
2025-02-28 |
视点制药公司 |
靶向HPTP-β(VE-PTP)和VEGF的多特异性抗体
|
|
SG11202105176QA
(en)
|
2018-12-20 |
2021-06-29 |
Sphingotec Gmbh |
Selenoprotein p in heart failure
|
|
WO2020128039A2
(en)
|
2018-12-21 |
2020-06-25 |
4TEEN4 Pharmaceuticals GmbH |
Therapy guidance and/or therapy monitoring for a treatment with angiotensin-receptor-agonist and/or a precursor thereof
|
|
JP2022535564A
(ja)
|
2019-06-04 |
2022-08-09 |
モレキュラー パートナーズ アクチェンゲゼルシャフト |
多選択性タンパク質
|
|
BR112022001417A2
(pt)
|
2019-08-15 |
2022-05-24 |
Sphingotec Gmbh |
Método para diagnóstico ou monitoramento de função renal ou diagnóstico de disfunção renal em pacientes pediátricos
|
|
JP2022546061A
(ja)
|
2019-08-30 |
2022-11-02 |
4ティーン4 ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ショック症治療のための治療法の誘導および/または治療法の監視
|
|
EP4073091A1
(en)
|
2019-12-11 |
2022-10-19 |
Molecular Partners AG |
Designed ankyrin repeat domains with altered surface residues
|
|
EP3871689A1
(en)
|
2020-02-26 |
2021-09-01 |
sphingotec GmbH |
Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
|
|
US20230193348A1
(en)
|
2020-02-27 |
2023-06-22 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock
|
|
KR20220145897A
(ko)
|
2020-02-27 |
2022-10-31 |
아드레노메드 아게 |
쇼크의 치료 또는 예방에 사용하기 위한 항-아드레노메둘린 (adm) 항체 또는 항-adm 항체 단편 또는 항-adm 비-ig 스캐폴드
|
|
US20230250166A1
(en)
|
2020-02-27 |
2023-08-10 |
Adrenomed Ag |
Anti-adrenomedullin (adm) binder for use in therapy of patients in shock
|
|
JP2023518731A
(ja)
|
2020-03-16 |
2023-05-08 |
4ティーン4 ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング |
コロナウイルスに感染した患者におけるdpp3
|
|
EP3922993A1
(en)
|
2020-06-12 |
2021-12-15 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 in patients infected with coronavirus
|
|
JP2023517717A
(ja)
|
2020-03-16 |
2023-04-26 |
シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング |
コロナウイルスに感染した患者におけるプロアドレノメデュリンまたはそのフラグメント、およびアドレノメデュリンに対する結合剤による治療
|
|
CN115916815A
(zh)
|
2020-05-06 |
2023-04-04 |
分子合作伙伴股份公司 |
新型锚蛋白重复结合蛋白及其用途
|
|
BR112022023049A2
(pt)
|
2020-05-14 |
2022-12-20 |
Molecular Partners Ag |
Proteínas multiespecíficas
|
|
EP4023218A1
(en)
|
2020-12-02 |
2022-07-06 |
S-Form Pharma |
Combination therapy for patients having acute and/or persistent dyspnea
|
|
EP4263607A1
(en)
|
2020-12-16 |
2023-10-25 |
Molecular Partners AG |
Novel slow-release prodrugs
|
|
AU2022232216A1
(en)
|
2021-03-09 |
2023-10-05 |
Molecular Partners Ag |
Protease cleavable prodrugs
|
|
US20240150475A1
(en)
|
2021-03-09 |
2024-05-09 |
Molecular Partners Ag |
Novel darpin based cd123 engagers
|
|
KR20230155464A
(ko)
|
2021-03-09 |
2023-11-10 |
몰리큘라 파트너스 아게 |
신규한 DARPin-기반 다중특이성 T-세포 인게이저
|
|
WO2022190010A1
(en)
|
2021-03-09 |
2022-09-15 |
Molecular Partners Ag |
Novel darpin based cd33 engagers
|
|
BR112023022439A2
(pt)
|
2021-04-26 |
2023-12-26 |
Celanese Eva Performance Polymers Llc |
Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
|
|
US20240272178A1
(en)
|
2021-06-18 |
2024-08-15 |
Sphingotec Gmbh |
A method for predicting sepsis and septic shock
|
|
EP4363859A1
(en)
|
2021-06-29 |
2024-05-08 |
berYsol GmbH |
Composite biomarker for the identification of selenium deficiency in a bodily fluid
|
|
EP4145456A1
(en)
|
2021-09-06 |
2023-03-08 |
Bayer AG |
Prediction of a change related to a macular fluid
|
|
WO2023110983A1
(en)
|
2021-12-14 |
2023-06-22 |
Molecular Partners Ag |
Designed repeat domains with dual binding specificity and their use
|
|
AU2023233838A1
(en)
|
2022-03-15 |
2024-09-26 |
Adrenomed Ag |
Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment
|
|
EP4562035A1
(en)
|
2022-07-29 |
2025-06-04 |
AdrenoMed AG |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
|
|
JP2025527173A
(ja)
|
2022-07-29 |
2025-08-20 |
4ティーン4 ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング |
敗血性ショックを有する患者におけるdpp3の増加の予測
|
|
WO2024028278A1
(en)
|
2022-08-01 |
2024-02-08 |
Molecular Partners Ag |
Charge modified designed repeat domains and their use
|
|
WO2024038307A1
(en)
|
2022-08-19 |
2024-02-22 |
Novartis Ag |
Dosing regimens for sars-cov-2 binding molecules
|
|
WO2024059686A2
(en)
*
|
2022-09-15 |
2024-03-21 |
The Regents Of The University Of California |
Darpin backbones and rigidified electron microscopy imaging scaffolds
|
|
WO2024126793A1
(en)
|
2022-12-15 |
2024-06-20 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 inhibitor for improvement of pulmonary function in critically ill patients
|
|
WO2024179981A1
(en)
|
2023-02-27 |
2024-09-06 |
Molecular Partners Ag |
Darpins for use in reducing renal accumulation of drugs
|
|
CN120731367A
(zh)
|
2023-03-17 |
2025-09-30 |
Pam治疗诊断有限公司 |
肽基甘氨酸α-酰胺化单加氧酶(PAM)的测定方法及其诊断用途
|
|
CN120857945A
(zh)
|
2023-03-29 |
2025-10-28 |
4Teen4制药有限公司 |
用于在血压下降的危重病患者中保护心肌和预防心肌损伤的dpp3抑制剂
|
|
WO2025068313A1
(en)
|
2023-09-25 |
2025-04-03 |
Sphingotec Gmbh |
A method for early diagnosis, early prediction, monitoring or prediction of severity of reduced graft function in a kidney transplantation patient
|
|
WO2025146491A1
(en)
|
2024-01-05 |
2025-07-10 |
Molecular Partners Ag |
Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent
|
|
WO2025229075A1
(en)
|
2024-05-03 |
2025-11-06 |
Sphingotec Gmbh |
A method for the specific determination of proenkephalin fragment 119-159
|
|
WO2025248139A1
(en)
|
2024-05-31 |
2025-12-04 |
4TEEN4 Pharmaceuticals GmbH |
Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof
|
|
EP4675277A1
(en)
|
2024-07-05 |
2026-01-07 |
Predemtec AG |
A method for diagnosing alzheimer´s disease or determining the risk of suffering from alzheimer´s disease
|